Hepatitis News : Gilead’s Hep C Combo Therapy Shows 100% Cure Rate in Small Study
A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis News » November 2012


emailprint

November 14, 2012

Gilead’s Hep C Combo Therapy Shows 100% Cure Rate in Small Study

Gilead Sciences’ pair of investigatory hepatitis C virus (HCV) therapies led to a 100 percent cure rate among a small cohort of patients, Reuters reports. The pharmaceutical company announced interim data from its ongoing Phase II ELECTRON study at the annual meeting of the American Association of the Study of Liver Disease (AASLD) in Boston. The news joined a flurry of research data from other companies, including Abbott Laboratories, whose own investigatory interferon-free drug regimen showed sustained virological response (SVR) rates above 90 percent. The potential market is large, considering that an estimated 5 million Americans are living with hep C and could use drug regimens that are both more tolerable and more effective than those available today.

Gilead studied 25 genotype 1-infected, treatment-naive patients taking a 12-week course of the investigational nucleotide sofosbuvir (formerly known as GS-7977) along with the NS5A inhibitor GS-5885, plus ribavirin. The viral loads of all 25 participants remained undetectable four weeks after completing the treatment, which proved well tolerated. The most common side effects were headache, fatigue, upper respiratory infection and nausea.

The pharmaceutical giant has just begun a Phase III study of sofosbuvir and GS-5885, both with and without ribavirin, for 12- and 24-week courses. Twenty percent of the 800-person study group has evidence of cirrhosis, promising results both more statistically significant and more relevant to the diverse hep C population.

To read the Reuters report, click here.

To read the Gilead release, click here.

Search: Hepatitis C, hep C, HCV, Gilead, 100 percent, cure, sustained virological response, SVR, American Association of the Study of Liver Disease, AASLD, Boston, Reuters, genotype 1, treatment-naive, sofosbuvir, nucleotide, GS-7977, NS5A inhibitor, GS-5885, ribavirin, viral load, ELECTRON, Phase II, Phase III


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (4 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Have you ever felt stigmatized for having hepatitis C?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.